An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab in Combination With Sacituzumab Govitecan Versus Pembrolizumab Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater Than or Equal to 50% Metastatic Non-small Cell Lung Cancer
MK-3475-D46 (KEYNOTE D46/EVOKE-03)
NCT05609968
 Recruiting
|
CIUSSS DE L'OUEST-DE-L'ILE-DE-MONTREAL
CENTRE HOSPITALIER DE ST. MARY
|
Non Small Cells - Lung |
Dr. Nicholas Meti
Olivia Lenaro
514-345-3511 poste 5507
|
A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib
SAFFRON
NCT05261399
Recruiting
|
CIUSSS DE L'OUEST-DE-L'ILE-DE-MONTREAL
CENTRE HOSPITALIER DE ST. MARY
|
Non Small Cells - Lung |
Dr. Nicholas Meti
Rachelle Dumas
514-345-3511 poste 3378
|
A Phase 1b/2 Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Investigational Agents for the Treatment of Participants With PD-1/L1-refractory Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Therapy
MK-3475-B98/KEYNOTE-B98
NCT04938817
Recruiting
|
CIUSSS DE L'OUEST-DE-L'ILE-DE-MONTREAL
CENTRE HOSPITALIER DE ST. MARY
|
Small Cells - Lung |
Dr. Adrian Langleben
Rachelle Dumas
514-345-3511 poste 3378
|
Groupe d'étude en oncologie du Québec